| Date | Title | Description |
| 01.04.2026 | Temasek-Novo consortium leads race for majority stake in nutraceuticals firm | Premium
(Representative image)
A consortium comprising Singapore state investment firm Temasek Holdings and Danish investor Novo Holdings, the ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a sel... |
| 12.03.2026 | Novo Holdings sees assets shrink by a 3rd in wake of Novo Nordisk's nosediving share price | Novo Holdings saw its assets shrink by a third last year as part of the fallout of Novo Nordisk’s nosediving share price.
The Copenhagen-based firm, which is the controlling shareholder of Novo Nordisk, oversaw total assets of 694 billion D... |
| 27.01.2026 | 2150 Fuels Climate Tech Boom with €210 Million Fund II, Propelling AUM to €500 Million | Climate venture firm 2150 successfully closed its €210 million second fund, boosting total assets to €500 million. The firm targets technology reshaping urban systems and powering sustainable cities. Its investments focus on critical climat... |
| 26.01.2026 | The Footprint Firm Closes First VC Fund At €76 Million For Northern Europe Climate Deep Tech | The Footprint Firm announced it has reached a final close of its debut venture capital vehicle, Footprint Fund I, raising €76 million to back pre-seed and seed climate deep-tech and scale-up companies across Northern Europe.
In a LinkedIn a... |
| 26.01.2026 | 2150 Closes €210 Million Second Fund, Lifting AUM To €500 Million | Venture firm 2150 said it has reached a final close on its second fund at €210 million, bringing the firm’s total assets under management to €500 million as it continues investing in technology companies aimed at reshaping cities and the in... |
| 20.01.2026 | Novo Holdings Invests in Surya Hospitals to Strengthen Access to High-Quality Women's and Children's Healthcare in India | SINGAPORE, Jan. 20, 2026 /PRNewswire/ -- Novo Holdings, a leading global healthcare and life sciences investor, today announced that it has made an investment in Surya Hospitals, the largest private women's and children's specialty hospital... |
| 18.11.2025 | Chromologics Raises €7M in Funding | Chromologics, a Copenhagen, Denmark-based company developing fermentation-based natural colours, raised €7M in funding.
The round was led by Novo Holdings, EIFO (the Export and Investment Fund of Denmark), Döhler Ventures, Collateral Good V... |
| 18.11.2025 | Novo Holdings Invests in Blue Planet to Build Zero-Waste Infrastructure Across Asia and Emerging Markets | SINGAPORE, Nov. 18, 2025 /PRNewswire/ -- Blue Planet Environmental Solutions, a Singapore-headquartered sustainability company pioneering technology-driven, IP-based waste management and upcycling solutions, today announced a strategic inve... |
| 18.11.2025 | Novo Holdings Invests in Blue Planet to Advance Circular Waste Solutions in Asia | Investment reinforces Novo Holdings' Planetary Health strategy to scale technologies
that enable a cleaner, more resource-efficient planet
SINGAPORE, Nov. 18, 2025 /PRNewswire/ -- Novo Holdings, a leading global life sciences and sustainabi... |
| 28.10.2025 | Hemab Therapeutics Secures $157M for Breakthrough Bleeding Disorder Therapies | Hemab Therapeutics closed a $157 million Series C funding round. The clinical-stage biotechnology firm targets severe, underserved bleeding and thrombotic disorders. This significant capital influx will accelerate two flagship programs: HMB... |
| 27.10.2025 | Hemab Therapeutics Raises $157M in Series C Financing | Hemab Therapeutics, a Cambridge, MA, and Copenhagen, Denmark-based clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, closed a $157m Series C financing... |
| 21.10.2025 | MATR Foods Raises €40M to Scale Production of Fermented Plant-Based Meat Alternatives | MATR Foods, a Danish producer of fermented plant-based meat alternatives, has completed a €40 million fundraise. It is claimed to be the largest food tech round to take place in Denmark this year, comprising €20 million in Series A equity a... |
| 21.10.2025 | MATR Foods Closes €40M Funding | MATR Foods, a Copenhagen, Denmark-based maker of fermented plant-based meat alternatives, closed a €40m funding round.
The round included €20m in Series A equity and €20m in venture debt. The deal was co-led by existing investor Novo Holdin... |
| 18.10.2025 | Mycoprotein Innovator The Protein Brewery Secures €30M, Targets US Market Expansion | The Protein Brewery, a Dutch mycoprotein innovator, secured €30M in Series B funding. This capital fuels global expansion, targeting US and European markets with its proprietary Fermotein ingredient. The company strategically pivoted to act... |
| 17.10.2025 | Investment Climate Podcast: Thijs Bosch of The Protein Brewery, How to Get Funded in 2025 | In this podcast series, Alex Shandrovsky interviews investors about benchmarks for funding Alt Proteins in 2025 and uncovers the investment playbooks of successful Climate Tech CEOs and Leading VCs.
Podcast Host Alex Shandrovksy is a strate... |
| 07.10.2025 | 55 North: €134 Million Secured For Quantum Technology Fund | 55 North announced the first close of its inaugural Fund I, having raised €134 million out of a targeted €300 million. This significant milestone establishes 55 North as the largest dedicated venture capital fund focused exclusively on quan... |
| 03.10.2025 | Denmark Unveils World's Largest Quantum Fund, Reshaping Tech Landscape | Denmark's 55 North emerges as the world's largest quantum technology venture fund. It achieved a €134 million first close for its €300 million inaugural fund. Backed by anchor investors EIFO and Novo Holdings, this landmark initiative targe... |
| 03.10.2025 | Quantum stocks Rigetti Computing and D-Wave surged double digits this week. Here’s what’s driving the big move | Rigetti Computing, D-Wave Quantum and Quantum Computing surged more than 20% this week.
Rigetti announced purchase orders for two of its quantum computing systems totaling $5.7 million.
The owner of drugmaker Novo Nordisk and the Danish gov... |
| 02.10.2025 | Copenhagen-based 55 North announces €134 million first close for record €300 million quantum technology fund | Copenhagen-based venture capital firm 55 North has announced the first close of its €300 million inaugural fund, raising €134 million with backing from anchor investors Novo Holdings and EIFO (Export and Investment Fund of Denmark). Positio... |
| 01.10.2025 | Crystalys Therapeutics: $205 Million Series A Raised For Transforming Gout Treatment | Crystalys Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for gout, a condition characterized by high levels of uric acid in the blood that can lead to painful arthritis flare-ups. The... |
| 22.09.2025 | The Protein Brewery Secures €30M to Advance Its Proprietary Mycoprotein | The Protein Brewery, a Dutch company producing fungi-based food ingredients, has secured €30 million in Series B funding.
The round saw participation from new investors Invest-NL and the Brabant Development Agency (BOM), alongside existing ... |
| 15.09.2025 | AMSilk Secures €52M to Unleash Industrial Scale Bio-Silk Revolution | AMSilk, a leading innovator in biotech-derived materials, has secured a substantial €52 million in new funding. This significant capital infusion propels the company's ambitious strategy to drastically scale its industrial production of adv... |
| 09.09.2025 | AMSilk Raises EUR 52M in Funding to Scale Industrial Production of Silk-Based Biomaterials | AMSilk has secured EUR 52 million in financing, aimed at scaling the industrial production of its silk-based protein materials. The investment round was led by ATHOS (AT Newtec), with additional participation from MIG Capital and Novo Holdi... |
| 09.09.2025 | AMSilk Raises €52M in Funding | AMSilk, a Neuried, Germany-based company developing advanced biomaterials made from silk-based proteins, raised €52M in funding.
The round was led by ATHOS (AT Newtec), with participation from existing investors MIG Capital and Novo Holding... |
| 03.09.2025 | Phasecraft Secures $34M: Quantum Computing Nears Real-World Impact | Quantum algorithms leader Phasecraft secured $34 million in Series B funding on September 2, 2025. This significant investment rapidly advances quantum computing from theoretical concepts to practical, real-world applications. Phasecraft ex... |
| 02.09.2025 | Phasecraft raises $34M to bring quantum computing closer to solving real-world challenges | Quantum algorithms company Phasecraft has raised $34 million in Series B funding to accelerate its breakthrough work and transform quantum computing’s theoretical promise into practical applications.
Quantum computing hardware and software ... |
| 02.09.2025 | Phasecraft secures $34M to accelerate practical quantum computing solutions
Send us a News Tip
EXTRACT THE SIGNAL FROM THE NOISE
Cookies | Quantum algorithm company Phasecraft Ltd. announced today that it has raised $34 million in new funding to accelerate its work to transform quantum computing’s theoretical promise into practical applications.
Founded in 2019, Phasecraft foc... |
| 14.07.2025 | Temasek eyes more Indian family-run businesses after Haldiram's deal | Credit: Reuters
Singapore's state investor Temasek is looking to invest more in Indian family-run businesses, a top executive said on Monday, months after it invested $1 billion in a popular domestic snacks company.
Family businesses in Ind... |
| 08.07.2025 | Novo Holdings weighs second India hospital deal | Premium
Karthik Narayanaswamy, partner and India head, Novo Holdings
Danish investor Novo Holdings, the controlling shareholder of drugmaker Novo Nordisk, is evaluating buying a stake in an Indian multi-speciality hospital chain that is bac... |
| 23.06.2025 | OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer | PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, tod... |
| 19.06.2025 | Novo Holdings Reports Strong Momentum in Asia Across Healthcare and Planetary Health in 2024 | Landmark investments, portfolio progress, and expanded presence position
Novo Holdings for long-term growth and impact in Asia
SINGAPORE, June 19, 2025 /PRNewswire/ -- Novo Holdings today released its Asia Investments Year in Review 2024, h... |
| 02.06.2025 | OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovar... | CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity
CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs
Promising signs of efficacy were observed in patie... |
| 30.05.2025 | GlycoEra AG: Pioneering a New Era in Autoimmune Disease Treatment | In the world of biotechnology, innovation is the lifeblood that fuels progress. GlycoEra AG is a shining example of this principle. Recently, the company secured $130 million in funding to advance its groundbreaking therapies for autoimmune... |
| 28.05.2025 | Former Cosun Executive Thijs Bosch Succeeds Sue Garfitt as CEO of The Protein Brewery | The Protein Brewery announced a leadership change with the appointment of Thijs Bosch as its new CEO, succeeding Sue Garfitt, who will transition into a non-executive role. This shift follows the company’s recent Series A fundraising and ma... |
| 27.05.2025 | GlycoEra AG raises $130 Million to advance therapies for autoimmune diseases |
GlycoEra’s proprietary platform enables the development of best-in-class degraders that target a broad spectrum of extracellular proteins. GlycoEra’s degraders are bispecific molecules that leverage a naturally occurring process to degrade... |
| 20.05.2025 | Indian healthcare AI startup Qure.AI aiming for IPO in two years, CEO says | Qure.AI, an India-based startup providing artificial intelligence tools to healthcare firms, is aiming to turn profitable in the next financial year and for an initial public offer (IPO) in two years, its CEO told Reuters.
The company, foun... |
| 14.05.2025 | Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future | SINGAPORE, May 13, 2025 /PRNewswire/ -- Novonesis, a world-leading biosolutions company, co-hosted its "Unlocking Value for a Sustainable Future" Partnering Day 2025 in Singapore on May 7 together with Novo Holdings and Flagship P... |
| 14.05.2025 | Novo Holdings Announces Investment in SCHOTT Poonawalla to Accelerate Growth and Innovation in Injectable Drug Packaging | SINGAPORE, May 14, 2025 /PRNewswire/ -- Novo Holdings, a global life sciences investor, today announced its investment in SCHOTT Poonawalla, India's leading provider of high-quality drug containment and delivery solutions for injectable pha... |
| 11.05.2025 | TPG's Bold Moves: A Dive into Recent Acquisitions | In the world of finance, the tides shift quickly. Recent moves by TPG, a global investment firm, showcase this dynamic landscape. TPG is not just a player; it’s a force. With two significant acquisitions, the firm is reshaping its portfolio... |
| 07.05.2025 | TPG's Bold Bet on Schott Poonawalla: A New Era in Pharmaceutical Packaging | In a significant move, TPG, a leading private equity firm, has acquired a 35% stake in Schott Poonawalla, a joint venture that merges the expertise of Serum Institute of India (SII) and Schott Pharma AG. This partnership is not just a finan... |
| 07.05.2025 | TPG to Acquire 35% Stake in SCHOTT Poonawalla from Serum Institute of India The transaction is expected to close in the first half of 2025. | Global investment firm TPG has entered into a binding agreement to acquire a 35% stake in SCHOTT Poonawalla Pvt Ltd, a leading drug packaging joint venture between Germany's SCHOTT Pharma and Serum Institute of India (SII), part of the Cyru... |
| 06.05.2025 | TPG acquires 35% stake in Schott Pharma from Serum Institute | US private equity firm TPG has entered into a binding agreement to acquire a 35% stake in the SCHOTT Poonawalla joint venture from Serum Institute of India (SII), the firms announced on Tuesday.
TPG Growth, TPG’s middle market and growth eq... |
| 06.05.2025 | TPG buys 35% stake in Schott Poonawalla, brings Novo Holdings as co-investor | Credit: Reuters
Private equity firm TPG said Tuesday it has picked up a 35% stake in pharmaceutical packaging company Schott Poonawalla, a joint venture between billionaire Adar Poonawalla-led Serum Institute of India (SII) and Schott Pharm... |
| 14.04.2025 | Sparrow Quantum Soars with €21.5 Million in Series A Funding | Sparrow Quantum is on the rise. The Copenhagen-based company has secured €21.5 million in Series A funding. This investment is a game-changer for the world of photonic quantum chips. Led by PensionDanmark, the funding round also saw contrib... |
| 12.04.2025 | Sparrow Quantum: €21.5 Million Raised For Advancing Photonic Quantum Innovation In Europe | Sparrow Quantum, a leading European photonic quantum chip supplier, announced it has secured €21.5 million in Series A funding to accelerate the development and commercialization of its world-leading quantum chip technology. PensionDanmark ... |
| 03.04.2025 | Novo Holdings to invest in KKR-backed fungal biotech firm Sylvan | Global life science investment firm Novo Holdings on Thursday announced a direct investment in KKR-backed fungal biotechnology solutions developer Sylvan. |
| 28.03.2025 | Supira Medical: $120 Million (Series E) Raised For Transforming The Percutaneous Ventricular Assist Device Market | Supira Medical – a clinical-stage Shifamed portfolio company – announced the completion of an oversubscribed Series E financing round, raising $120 million to accelerate the company’s mission of transforming the percutaneous ventricular ass... |
| 27.03.2025 | Supira Medical's $120 Million Leap: A New Era for Heart Health | In the heart of Silicon Valley, a revolution is brewing. Supira Medical, a clinical-stage company based in Los Gatos, California, has just secured a whopping $120 million in an oversubscribed Series E financing round. This significant capit... |
| 26.03.2025 | Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States | LOS GATOS, Calif., March 26, 2025 /PRNewswire/ -- Supira Medical, Inc. (Supira), a clinical-stage Shifamed portfolio company, today announced the successful completion of an oversubscribed Series E financing round, raising $120M to accelera... |
| 20.03.2025 | Climatetech VC 2150 closes near €200M for Fund II | Climatetech VC 2150 announced today that it has closed almost €200 million for Fund II, with support from previous and new institutional investors, including Augustinus Fonden, Novo Holdings, EIFO, Carbon Equity, Church Pension Group, and f... |
| 03.03.2025 | Novo Holdings and TA Associates Invest in Biocomposites | Biocomposites, a Keele, UK-based medical devices company, received an investment from Novo Holdings and TA Associates.
The amount of the deal was not disclosed. As part of the transaction, TA, Biocomposites’ majority shareholder since 2017,... |
| 25.02.2025 | Esco Lifesciences Group and Allwin Medical Devices Announce Strategic Partnership | SINGAPORE and ANAHEIM, USA – Media Outreach Newswire – 25 February 2025 – Allwin Medical Devices Inc. (“Allwin”), a leading manufacturer of a wide range of medical devices addressing women’s health (IVF), urology, gastroenterology and inter... |
| 15.02.2025 | Newleos Therapeutics: A New Dawn in Neuropsychiatric Treatment | In the world of mental health, the need for innovation is as urgent as a fire alarm. Newleos Therapeutics has stepped into this arena with a bold vision and a hefty $93.5 million in Series A funding. This clinical-stage neuroscience company... |
| 14.02.2025 | Newleos Therapeutics: $93.5 Million (Series A) Raised For Transforming Treatment Of Neuropsychiatric Disorders | Newleos Therapeutics—a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development—announced the closing of an oversubscribed $93.5 million Series A financing. Goldman Sachs Alternatives led ... |
| 13.02.2025 | OnCusp Therapeutics: A New Hope for Ovarian Cancer Patients | In the realm of cancer treatment, hope often feels like a flickering candle in a storm. Yet, OnCusp Therapeutics is igniting that flame with its recent FDA Fast Track Designation for CUSP06, a promising therapy for platinum-resistant ovaria... |
| 13.02.2025 | Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicines | -Newleos aims to develop first-in-class and best-in-class therapies to address the need for safer and more efficacious treatment options for major mental health conditions-
-Multiple clinical-stage programs licensed from Roche, ready for pr... |
| 12.02.2025 | OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer | PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, tod... |
| 05.02.2025 | Funding Is Flush For Startups Focused On Treating Pain | 3 Shares Email Facebook Twitter LinkedIn
Big pharma and startups alike have put huge efforts over the years into finding effective and nonaddictive treatments for pain. For the most part, it’s been a slow-going slog.
Last week, however, the... |
| 16.01.2025 | Coave Therapeutics: €32 Million (Series A) Raised For Advancing Genetic Medicines | Coave Therapeutics – a company advancing the future of genetic medicines – announced the raising of €32 million ($33 million) in Series A funding. The funding was co-led by Novo Holdings A/S and Bpifrance, with Invus and UI Investissement p... |
| 15.01.2025 | Manipal Hospitals backer Novo Holdings names former KKR exec as India head | Premium
Karthik Narayanaswamy
Danish investment firm Novo Holdings, which has invested in Manipal Hospitals and Qure.ai Technologies in India, has appointed a new head for its local operations as it looks to ramp up its activities in the So... |
| 14.01.2025 | Windward Bio: Charting New Waters in Immunology with $200 Million Series A Financing | In the vast ocean of biopharmaceutical innovation, Windward Bio has set sail with a robust $200 million Series A financing. This private, clinical-stage company aims to navigate the turbulent waters of immunological diseases, focusing on se... |
| 13.01.2025 | Windward Bio launches with $200 million Series A financing round |
Windward Bio’s lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the... |
| 11.01.2025 | AnaCardio's €19 Million Leap: A New Dawn for Heart Failure Treatment | In the world of biopharmaceuticals, every funding round can feel like a heartbeat—vital and pulsating with potential. AnaCardio, a clinical-stage startup based in Stockholm, has just secured €19 million (approximately USD 19 million) to adv... |
| 10.01.2025 | Numab Therapeutics: A Financial Surge in the Fight Against Cancer | In the world of biotechnology, where innovation meets investment, Numab Therapeutics has made headlines with its recent financial maneuvering. The Swiss company, known for its pioneering work in multi-specific antibodies, has successfully c... |
| 10.01.2025 | AnaCardio pumps €19 million into heart failure treatment innovation | AnaCardio, a clinical-stage biopharmaceutical startup headquartered in Stockholm, has secured €17.8 million in a Series A extension round to develop their drug candidate AC01.
The financing was co-led by Novo Holdings, Pureos Bioventures, a... |
| 10.01.2025 | Numab Therapeutics raises $55M for antibody-based immunotherapies | Biotech Numab Therapeutics has raised $55 million, bringing its Series C fundraise to $197 million.
Numab is a clinical-stage company developing multi-specific antibody-based immunotherapies for inflammation and cancer.
Its developed a repr... |
| 09.01.2025 | FIRE1: $120 Million Funding Raised For Transforming Heart Failure Care | FIRE1 – a leading connected medical device solutions company – announced the completion of a $120 million financing round to accelerate the company’s mission to transform the lives of millions of people living with heart failure. The fundin... |
| 09.01.2025 | Numab raises additional CHF50 million |
In 2024 Numab caused a stir with the acquisition of the biotech’s spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion. Numab’s immuno-oncology therapeutic NM26 entered the clinic and the company started a collabo... |
| 09.01.2025 | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure
Thu, Jan 09, 2025 09:00 CET Report this content
Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ... |
| 08.01.2025 | FIRE1 Secures $120M for Heart Failure Management Platform | What You Should Know:
– FIRE1, a connected medical device company, announced it has secured $120M in funding to advance its mission to transform the lives of millions of people living with heart failure. The round was led by Polaris Partner... |
| 07.01.2025 | FIRE1 Secures $120M Financing | FIRE1, a Dublin, Ireland-based connected medical device solutions company, raised $120M in funding.
The round was led by Polaris Partners and Elevage Medical Technologies, joined by new investors Sands Capital and Longitude Capital, and exi... |
| 07.01.2025 | Denise Ruffner: Fostering Innovation Through Strategic Partnerships in Quantum | Share
Tweet
Share
Share
Email
The rise of quantum computing presents a unique challenge for business leaders: how to prepare for a technology that’s both revolutionary and still evolving. For many organizations, particularly in finance, bui... |
| 07.01.2025 | FIRE1 heats up with $120M for its heart failure monitor implant | Things are heating up for FIRE1, which posted a $120 million funding round to support its implant for tracking the hidden signs of heart failure.
The Dublin-based company also announced that the FDA has handed down a breakthrough designatio... |
| 06.01.2025 | Orbis Medicines: Oral Macrocycle Drug Discovery Company Raises €90 Million (Series A) | Orbis Medicines – a leader in oral macrocycle drug discovery – announced today the closing of a €90 million Series A funding round, bringing the total amount raised by the company to €116 million. The funding round will support the developm... |
| 24.12.2024 | SiteOne Therapeutics: A New Dawn in Non-Opioid Pain Management | In a world where pain management often leads to addiction, SiteOne Therapeutics is carving a new path. The San Francisco-based biotech has just secured $100 million in Series C funding, led by Novo Holdings. This investment marks a signific... |
| 18.12.2024 | Novo Holdings leads SiteOne's $100M series C for non-opioid pain treatments | SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target the peripheral nervous system instead of the central nervous system.
The biotech’s series C financing was led by Novo... |
| 16.12.2024 | Novo Nordisk инвестирует $1,2 млрд в новое производственное предприятие в Дании | Датский фармацевтический гигант Novo Nordisk заявил, что создаст в Оденсе производственный объект, предназначенный для выпуска различных видов продукции для лечения редких заболеваний, таких как гемофилия.
Строительные работы уже начались и... |
| 08.12.2024 | Nuvig: $161 Million (Series B) Raised To Develop Novel Immunomodulatory Therapeutics | Nuvig Therapeutics – a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases – announced the closing of a $161 million Series B round. The funding was co-led b... |
| 05.12.2024 | Nuvig Therapeutics Raises $161M in Series B Funding | Nuvig Therapeutics, a Menlo Park, CA-based privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, raised $161M in Series B funding.
The round was led by Sanofi... |
| 25.11.2024 | Novo Holdings to Acquire Benchmark Genetics | Copenhagen, Denmark-based Novo Holdings announced that it has agreed to acquire Benchmark Genetics, a Bergen, Norway-based fish genetics company, from Benchmark Holdings plc for an enterprise value of up to £260M.
Led by CEO Trond Williksen... |
| 20.11.2024 | Alentis Therapeutics: $181.4 Million (Series D) Raised For Advancing Clinical Development Of Anti-Claudin-1 ADCs | Alentis Therapeutics – a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis – announced that it has raised $181.4 million in Series D financing, supported by a syndicate of t... |
| 18.11.2024 | Quanta Dialysis Technologies: Kidney Care Company Closes Over $60 Million (Series E Preferred Stock) | Quanta Dialysis Technologies, a leader in transforming kidney care through its Quanta Dialysis System, announced it has closed its oversubscribed Series E Preferred Stock financing round, raising more than $60 million of additional capital.... |
| 13.11.2024 | Alentis Therapeutics Secures $181.4 Million to Pioneer Cancer Treatments | In a bold move to reshape cancer treatment, Alentis Therapeutics has successfully raised $181.4 million in an oversubscribed Series D funding round. This infusion of capital, led by OrbiMed and co-led by Novo Holdings and Jeito Capital, sig... |
| 13.11.2024 | Alentis Therapeutics: $181.4 Million (Series D) Raised To Develop Treatments For Claudin-1 Tumors | Alentis Therapeutics – a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis – announced that it has raised $181.4 million in Series D funding, supported by a syndicate of top... |
| 12.11.2024 | Alentis Therapeutics raises $181.4 million in oversubscribed series D round | Normal 0 false false false EN-GB X-NONE AR-SA
Besides OrbiMed, Novo Holdings and Jeito Capital, Alentis Therapeutics’ series D round saw the participation of new investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Hea... |
| 24.10.2024 | AMSilk and Ajinomoto Join Forces to Advance Bio-Based Silk Proteins for High-Performance, Biodegradable Textiles | German biotech company AMSilk GmbH has entered into a long-term partnership with Ajinomoto Foods Europe, an affiliate of the Ajinomoto Group, to manufacture biobased silk proteins at large scale for biodegradable textiles.
The collaboration... |
| 04.10.2024 | Qure.ai: $65 Million (Series D) Raised To Expand Into More Markets | Mumbai-based global healthcare AI company Qure.ai announced it raised a $65 million Series D funding round. This funding round will expedite expansion in the US market and other geographies, invest more in foundational AI models, and enable... |
| 27.09.2024 | Qure.ai raises Series D funding led by Lightspeed, 360 ONE Asset | Prashant Warier, co-founder and chief executive, Qure.ai
Qure.ai Technologies Pvt. Ltd, a health-tech startup that uses artificial intelligence for medical imaging diagnostics, has raised $65 million ( Rs 544 crore) in Series D funding roun... |
| 27.09.2024 | Lightspeed and 360 ONE Asset Lead USD 65 Mn Series D Funding for Qure.ai's Global Healthcare AI Expansion With the raised funds, Qure.ai aims to expand in the US and global markets, advance AI models,... | AI-driven healthcare startup Qure.ai has raised USD 65 million in its Series D funding round led by Lightspeed and 360 ONE Asset, with participation from other prominent investors such as Merck Global Health Innovation Fund and Kae Capital.... |
| 27.09.2024 | Global healthcare AI startup Qure.ai raises $65M in Series D round led by Lightspeed and 360One Asset
Recommended Stories For You | AI-driven healthcare startup Qure.ai has raised $65 million in its Series D funding round. The round was led by Lightspeed and 360 ONE Asset, with participation from Merck Global Health Innovation Fund and Kae Capital. Existing investors su... |
| 26.09.2024 | Qure.ai Closes $65M Series D Funding | Qure.ai, a Mumbai, India-based healthcare AI innovator, raised $65M in Series D funding.
The round was led by Lightspeed and 360 ONE Asset, joined by Merck Global Health Innovation Fund and Kae Capital. Existing investors Novo Holdings, Hea... |
| 26.09.2024 | Qure.ai, a Global Healthcare AI Innovator, Raises $65 Million in Series D Funding Led by Lightspeed and 360One Asset | Qure.ai, a global healthcare AI innovator, has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the US market and other geographies, increase investment into foundational AI model... |
| 25.09.2024 | Qure.ai Raises $65M to Expand Healthcare AI Solutions Globally | What You Should Know:
– Qure.ai, a prominent global innovator in healthcare AI, has successfully closed a $65M in Series D funding round led by Lightspeed and 360 ONE Asset, with contributions from Merck Global Health Innovation Fund and Ka... |
| 16.09.2024 | Denmark’s Matr Foods Secures €20M EU Loan for Mycelium Meat Factory | 4 Mins Read Danish meat analogue startup Matr Foods has received €20M in debt funding from the European Investment Bank to open a large-scale mycelium meat facility.
Mycelium meat maker Matr Foods has received a €20M loan from the EU’s lend... |
| 13.09.2024 | MATR Foods Secures €20M From European Investment Bank to Construct First Full-Scale Facility | Danish meat alternatives producer MATR Foods has signed a €20 million loan agreement with the European Investment Bank (EIB).
The funding, which is supported by the European Commission’s InvestEU initiative, will allow MATR to construct its... |
| 31.08.2024 | Catalent delays filing of annual report | Healthcare & PharmaceuticalsCommercial Strategy
Catalent delays filing of annual report
By ReutersAugust 30, 20249:32 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A general view of the dr... |
| 28.07.2024 | The Surge of Innovation: How Magenta Medical and Brenig Therapeutics are Shaping the Future of Healthcare | In the world of healthcare, innovation is the lifeblood that keeps the industry thriving. Two companies, Magenta Medical and Brenig Therapeutics, are at the forefront of this revolution. With significant funding rounds recently completed, t... |
| 26.07.2024 | Magenta Medical: Heart Pump Company Raises $105 Million | Magenta Medical, the developer of Elevate (the world’s smallest heart pump), announced it had closed a $105 million funding round led by global healthcare investment firm Novo Holdings. The new investors Viking Global Investors and RA Capit... |
| 18.07.2024 | Asceneuron's $100M Series C Funding Boosts Alzheimer's Disease Research | Asceneuron, a Lausanne-based clinical-stage biotech company, has recently announced the successful completion of a $100 million Series C financing round. This significant funding boost, led by Novo Holdings and supported by EQT Life Science... |
| 16.07.2024 | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round
Tue, Jul 16, 2024 09:15 CET Report this content
EQT Life Sciences has invested in Asceneuron’s oversubscr... |
